Historically, the antimitotic drug colchicine has been, and still is, extensively used for the management of consequences of gout and pseudogout, that is, of inflammation attacks [45], which are caused by uric acid crystals that activate the NALP3 inflammasome [32]. The gene discussed is NLRP3; the disease is chondrocalcinosis.